Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Repligen Earns Pfizer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Repligen Earns Pfizer Milestone

Receives $1 million under SMA development pact

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Repligen Corp. has received a $1 million milestone payment from Pfizer under an exclusive worldwide licensing agreement for the development of compounds to treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two.
 
The companies signed the agreement in January 2013, and since then, Repligen has received $7 million in upfront and milestone payments. Repligen is eligible to receive as much as $63 million in additional milestones, as well as royalties on any future sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics